October 2021 OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT
October 2021 OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
October 2021 OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®
October 2021 OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of CoVepiT
October 2021 OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with BI 765063
October 2021 OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance
October 2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement for FR 104
October 2021 OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230